Arcturus’ unlocked nucleomonomer agents (UNAs) can improve the in vivo efficiency of small interfering RNA (siRNA)-mediated gene silencing and potentially improve the efficiency of messenger RNA (mRNA)-mediated protein replacement. UNAs are RNA analogues in which the C2′-C3′ bond of the ribose ring is absent (see figure below).
One or more UNAs can be positioned strategically along a nucleic acid strand to manipulate the chemical properties of the molecule. Addition of a single UNA in siRNA therapeutics can enable more efficient suppression of target protein production.
July 9, 2018
Arcturus Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
June 18, 2018
Arcturus Therapeutics to Present at the JMP Securities Life Sciences Conference
May 31, 2018
Arcturus Announces Management Appointments; Company Founder Joseph E. Payne Reinstated as President and CEO